Crosstalk between inflammation and thrombosis

被引:297
作者
Esmon, CT
机构
[1] Univ Oklahoma, Hlth Sci Ctr,Dept Pathol, Howard Hughes Med Inst, Cardiovasc Biol Res Program,Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA
[2] Univ Oklahoma, Hlth Sci Ctr,Dept Biochem, Howard Hughes Med Inst, Cardiovasc Biol Res Program,Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA
[3] Univ Oklahoma, Hlth Sci Ctr,Dept Mol Biol, Howard Hughes Med Inst, Cardiovasc Biol Res Program,Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA
关键词
endotoxin; macrophages; fibrinogen;
D O I
10.1016/j.maturitas.2003.10.015
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Inflammation shifts the hemostatic mechanisms in favor of thrombosis. Multiple mechanisms are at play including up regulation of tissue factor leading to the initiation of clotting, amplification of the clotting process by augmenting exposure of cellular coagulant phospholipids, inhibition of fibrinolysis by elevating plasminogen activator inhibitor 1 (PAI-1) and decreases in natural anticoagulant pathways, particularly targeted toward down regulation of the protein C anticoagulant pathway through multiple mechanisms. The decreased function of the natural anticoagulant pathways may be particularly problematic because these appear to play a role in dampening inflammatory responses. The protein C anticoagulant pathway provides a useful model for the impact of inflammation on coagulation. This pathway plays a major role in preventing microvascular thrombosis. The pathway is initiated when thrombin binds to thrombomodulin (TM) on the surface of the endothelium. An endothelial cell protein C receptor (EPCR) augments protein C activation by the thrombin-TM complex more than 10-fold in vivo. EPCR is shed from the endothelium by inflammatory mediators and thrombin. EPCR binds to activated neutrophils in a process that involves protemase 3 and Mac-1 and appears to inhibit leukocyte extravisation. EPCR can undergo translocation from the plasma membrane to the nucleus where it redirects gene expression. During translocation it can carry activated protein C (APC) to the nucleus, possibly accounting for the ability of APC to modulate inflammatory mediator responses in the endothelium. TNF alpha and other inflammatory mediators can down-regulate EPCR and TM and IL-6 can depress levels of protein S in experimental animals. Inhibition of protein C pathway function increases cytokine elaboration, endothelial cell injury and leukocyte extravisation in response to endotoxin, processes that are decreased by infusion of APC. In vitro, APC inhibits TNF alpha elaboration from monocytes and to block leukocyte adhesion to selectins. Since thrombin can elicit many inflammatory responses in microvascular endothelium, loss of control of microvascular thrombin generation due to impaired protein C pathway function probably contributes to microvascular dysfunction in sepsis. (C) 2004 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:305 / 314
页数:10
相关论文
共 79 条
  • [11] Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N
    Campbell, WD
    Lazoura, E
    Okada, N
    Okada, H
    [J]. MICROBIOLOGY AND IMMUNOLOGY, 2002, 46 (02) : 131 - 134
  • [12] CARIOU R, 1986, NEW ENGL J MED, V314, P1193
  • [13] Carson CW, 2000, J RHEUMATOL, V27, P384
  • [14] The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor κB and mitogen-activated protein kinase pathways
    Conway, EM
    Van de Wouwer, M
    Pollefeyt, S
    Jurk, K
    Van Aken, H
    De Vriese, A
    Weitz, JI
    Weiler, H
    Hellings, PW
    Schaeffer, P
    Herbert, JM
    Collen, D
    Theilmeier, G
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 196 (05) : 565 - 577
  • [15] TUMOR NECROSIS FACTOR SUPPRESSES TRANSCRIPTION OF THE THROMBOMODULIN GENE IN ENDOTHELIAL-CELLS
    CONWAY, EM
    ROSENBERG, RD
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 1988, 8 (12) : 5588 - 5592
  • [16] THROMBIN RECEPTOR FUNCTION AND CARDIOVASCULAR-DISEASE
    COUGHLIN, SR
    [J]. TRENDS IN CARDIOVASCULAR MEDICINE, 1994, 4 (02) : 77 - 83
  • [17] DRAKE TA, 1989, AM J PATHOL, V134, P1087
  • [18] REPLACEMENT THERAPY WITH A MONOCLONAL-ANTIBODY PURIFIED PROTEIN-C CONCENTRATE IN NEWBORNS WITH SEVERE CONGENITAL PROTEIN-C DEFICIENCY
    DREYFUS, M
    MASTERSON, M
    DAVID, M
    RIVARD, GE
    MULLER, FM
    KREUZ, W
    BEEG, T
    MINFORD, A
    ALLGROVE, J
    BERGMANN, F
    MITCHELL, VE
    HAWORTH, C
    NELSON, K
    SCHWARZ, HP
    [J]. SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1995, 21 (04) : 371 - 381
  • [19] TREATMENT OF HOMOZYGOUS PROTEIN-C DEFICIENCY AND NEONATAL PURPURA FULMINANS WITH A PURIFIED PROTEIN-C CONCENTRATE
    DREYFUS, M
    MAGNY, JF
    BRIDEY, F
    SCHWARZ, HP
    PLANCHE, C
    DEHAN, M
    TCHERNIA, G
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (22) : 1565 - 1568
  • [20] EDGINGTON TS, 1991, THROMB HAEMOSTASIS, V66, P67